DLBCL, Old Age; Debility
Conditions
Brief summary
Multi-center retrospective analysis of patients with DLBCL aged ≥80 years old treated with R-CHOP-14 compared to other regimens. Patient data including baseline characteristics, histology, dose intensity and treatment outcomes will be extracted from hospital medical electronic records. Relative dose intensity (RDI) will be calculated as the percentage of the dose intensity achieved divided by the intended dose intensity. Primary endpoints are overall (OS), progression-free (PFS) and event-free survival (EFS), defined as time from diagnosis to death, death or progression/relapse, progression/relapse or treatment discontinuation.
Interventions
None listed
Sponsors
University Hospital, Saarland
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
80 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* histologically proven, untreated diffus large B-cell lymphoma (DLBCL) * diagnosis between 2005 - 2019 * age ≥80 at diagnosis
Exclusion criteria
\- diagnosis revision at a later timepoint
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) death or progression/relapse, progression/relapse or treatment discontinuation. | through study completion, an average of 2 years | time from diagnosis to death |
| Progression-free survival (PFS) | through study completion, an average of 2 years | time from diagnosis to death or progression/relapse |
| Event-free survival (EFS) | through study completion, an average of 2 years | defined as time from diagnosis to death or progression/relapse or treatment discontinuation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relative Dose intensity | within the treatment period, up to 36 weeks | Percentage of the dose intensity achieved divided by the intended dose intensity |
Countries
Germany
Outcome results
None listed